FY2026 Earnings Estimate for PMVP Issued By HC Wainwright

Key Points

• HC Wainwright has issued a FY2026 earnings estimate for PMV Pharmaceuticals, projecting a loss of ($1.63) per share, which is significantly lower than the consensus estimate of ($1.06) per share.
• PMV Pharmaceuticals reported a quarterly loss of ($0.41) EPS, missing analysts' expectations of ($0.39) by ($0.02) in its latest earnings release.
• Insider trading activity included CEO David Henry Mack selling 58,411 shares, resulting in a 9.82% decrease in ownership, while major shareholder Orbimed Advisors sold 500,000 shares for $900,000.

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) - HC Wainwright issued their FY2026 earnings estimates for shares of PMV Pharmaceuticals in a research report issued on Friday, September 19th. HC Wainwright analyst R. Burns expects that the company will earn ($1.63) per share for the year. The consensus estimate for PMV Pharmaceuticals' current full-year earnings is ($1.06) per share.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.02).

PMV Pharmaceuticals Trading Up 6.5%

PMVP opened at $1.31 on Monday. The company's fifty day moving average price is $1.41 and its two-hundred day moving average price is $1.17. The company has a market cap of $69.42 million, a price-to-earnings ratio of -0.83 and a beta of 1.52. PMV Pharmaceuticals has a 1-year low of $0.81 and a 1-year high of $1.84.

Insiders Place Their Bets

In other PMV Pharmaceuticals news, CEO David Henry Mack sold 58,411 shares of the stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $1.06, for a total transaction of $61,915.66. Following the completion of the transaction, the chief executive officer owned 536,133 shares in the company, valued at $568,300.98. This trade represents a 9.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Orbimed Advisors Llc sold 500,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $1.80, for a total transaction of $900,000.00. Following the completion of the transaction, the insider owned 5,975,291 shares of the company's stock, valued at $10,755,523.80. This trade represents a 7.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 614,627 shares of company stock worth $1,021,505 over the last quarter. 7.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in PMVP. Shay Capital LLC purchased a new position in PMV Pharmaceuticals during the 2nd quarter valued at $26,000. Squarepoint Ops LLC lifted its stake in PMV Pharmaceuticals by 68.7% during the 4th quarter. Squarepoint Ops LLC now owns 73,015 shares of the company's stock valued at $110,000 after acquiring an additional 29,722 shares during the period. Northern Trust Corp lifted its stake in shares of PMV Pharmaceuticals by 23.2% in the 4th quarter. Northern Trust Corp now owns 107,340 shares of the company's stock worth $162,000 after purchasing an additional 20,190 shares during the period. Assenagon Asset Management S.A. lifted its stake in shares of PMV Pharmaceuticals by 128.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 263,059 shares of the company's stock worth $279,000 after purchasing an additional 148,021 shares during the period. Finally, Peapod Lane Capital LLC raised its stake in PMV Pharmaceuticals by 9.8% during the 1st quarter. Peapod Lane Capital LLC now owns 489,370 shares of the company's stock worth $533,000 after acquiring an additional 43,626 shares during the period. 90.20% of the stock is owned by hedge funds and other institutional investors.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.